Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPN-101 in Progressive Supranuclear Palsy (PSP)
NCT04993768Phase 2Completed
- Sponsor
- Transposon Therapeutics, Inc.
- Start
- Dec 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of censavudine in progressive supranuclear palsy (PSP), sponsored by Transposon Therapeutics, Inc.. Started Dec 2021; status: completed.
02
Drugs
censavudine
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT04993768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04993768.